Why This Site Exists
WeightLossPills.com launched in 2026. The timing wasn't random. Between late 2025 and early 2026, the FDA approved several new GLP-1 weight loss medications — including Foundayo (orforglipron), new oral semaglutide formulations, and a wave of drugs moving fast through Phase 3 trials.
Patients searching for clear information were mostly landing on outdated pharmacy pages, manufacturer press releases, or forums. We built this site to fill that gap: one place where every approved weight loss medication and the drugs coming next are covered and reviewed by physicians.
What We Cover
Every GLP-1 weight loss medication currently approved in the US — Ozempic, Wegovy, Zepbound, Rybelsus, Oral Wegovy, and Foundayo. We also cover late-stage pipeline drugs through our Future Meds section, so patients can follow what's coming before it's approved.
Pages are updated when trial data, dosing guidance, or approvals change — not on a fixed schedule. If something material changes, we update it.
Who Reviews the Content
Every page on this site is written or reviewed by a licensed physician with direct prescribing experience in weight loss medicine. Our reviewing physicians include the team below — we'll be adding more as the site grows.
Editorial Independence
We don't accept payment from pharmaceutical companies to shape coverage. Medication rankings and recommendations are based on published trial data and clinical experience, not commercial relationships. You can read the full details on our Review Process page.
Get in Touch
Questions, corrections, or something we've missed — contact us. We read everything.